When we first met the SynapticAI founding team eighteen months ago, they were three researchers sharing a cramped laboratory at MIT's McGovern Institute for Brain Research. They had a prototype, a body of peer-reviewed research spanning nearly a decade, and a conviction that non-invasive neural interfaces were approaching a technical inflection point. We agreed. Today, we are thrilled to formalize that conviction with capital.
SynapticAI has developed a headset-form-factor device that uses advanced EEG signal processing, novel dry electrode arrays, and proprietary transformer-based neural decoding models to achieve a resolution of neural communication previously only possible with surgically implanted electrodes. This is a genuinely remarkable technical achievement, and it opens the door to an enormous range of applications that were simply not feasible with earlier non-invasive systems.
The Technology
At the core of SynapticAI's platform is a machine learning stack trained on what the company describes as the largest proprietary dataset of high-density EEG recordings ever assembled. The dataset, built in collaboration with four major academic medical centers, comprises over 40,000 hours of annotated neural activity from participants performing complex motor and cognitive tasks.
The decoding model is a custom sparse transformer architecture that processes multi-channel EEG signals in under 15 milliseconds end-to-end, enabling real-time neural control of external devices. In independent benchmarks conducted by the company and replicated by a third-party laboratory at Johns Hopkins, the system achieved a 94% command accuracy rate for a 32-class motor imagery task — a figure that rivals some partially invasive systems currently in clinical trials.
The hardware itself is equally impressive. SynapticAI's dry electrode array uses a proprietary conductive polymer material developed in-house that maintains low-impedance skin contact without conductive gel, solving one of the most persistent usability problems in non-invasive BCI deployment.
Why We Invested
Deep-tech investments at the seed stage require us to evaluate not just the current state of a technology, but the trajectory of the underlying science. With SynapticAI, the signal was clear on both dimensions.
First, the founding team is exceptional. CEO Dr. Marcus Okonkwo holds a doctorate in neural engineering from MIT and completed a postdoctoral fellowship at the Salk Institute for Biological Studies. CTO Dr. Anya Petrov is a former research scientist at OpenBCI with a track record of shipping real-world neural interface hardware. Together with their team of twelve researchers and engineers, they represent one of the most technically credible founding teams we have encountered in five years of investing.
Second, the market opportunity is enormous and underserved. An estimated 17 million people in the United States alone have conditions — including ALS, spinal cord injury, and severe cerebral palsy — that could benefit meaningfully from high-resolution neural communication technology. Current assistive communication solutions are slow, unreliable, and deeply frustrating for users. SynapticAI's system changes the equation.
Third, the regulatory pathway is substantially cleaner than for invasive systems. Non-invasive BCI devices occupy a more favorable position in the FDA's device classification framework, enabling a faster path to first commercial applications in the augmentative and alternative communication space.
Use of Funds
The $2.5 million seed round will be used to fund three primary initiatives over the next eighteen months. The company will complete a 120-person clinical study at Columbia University Medical Center to gather the regulatory-quality data needed to support a 510(k) submission for their first clinical indication. They will also expand the engineering team with three additional ML researchers and two hardware engineers to accelerate the development of their second-generation device. Finally, the funds will support the establishment of a commercial pilot program with two partner rehabilitation hospitals.
The vision of SynapticAI is a world where the physical limitations imposed by neurological injury or disease no longer constrain a person's ability to communicate, create, and participate in society. We are building the technical foundation for that world, and Neuron Factory shares our conviction that it is achievable within this decade.
— Dr. Marcus Okonkwo, CEO, SynapticAI
Looking Ahead
We believe SynapticAI has the potential to become one of the defining companies in the neurotechnology sector over the next decade. The combination of world-class technical talent, a proprietary data moat, and a genuine unmet clinical need creates a foundation for durable competitive advantage that is rare to find at the seed stage.
Neuron Factory will take a board seat as part of this investment, and James Caldwell, Managing Partner, will work closely with the SynapticAI team as a strategic advisor throughout the clinical trial and early commercialization phases.
We will share more about SynapticAI's progress as the company advances through its clinical milestones. If you are a researcher, clinical partner, or strategic customer interested in engaging with the SynapticAI team, please reach out through our contact page.